Prediction and estimation of pulmonary response and elastance evolution for volume-controlled and pressure-controlled ventilation

Citation for published version (APA):

Document status and date:
Published: 01/02/2022

DOI:
10.1016/j.bspc.2021.103367

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.
Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 17 Sep. 2023
Prediction and estimation of pulmonary response and elastance evolution for volume-controlled and pressure-controlled ventilation

Qianhui Sun a,*, J. Geoffrey Chase a, Cong Zhou a, b, Merryn H. Tawhai c, Jennifer L. Knopp a, Knut Möller d, Serge J Heines e, Dennis C. Bergmans f, Geoffrey M. Shaw g

a Department of Mechanical Engineering, Dept of Mechanical Eng, Centre for Bio-Engineering, University of Canterbury, Christchurch, New Zealand
b School of Civil Aviation, Northwestern Polytechnical University, China
c Auckland Biomedical Engineering Institute, The University of Auckland, Auckland, New Zealand
d Institute for Technical Medicine, Furtwangen University, Villingen-Schwenningen, Germany
e Department of Intensive Care, School of Medicine, Maastricht University, Maastricht, Netherlands
f Department of Intensive Care, Christchurch Hospital, Christchurch, New Zealand

ABSTRACT

Mechanical ventilation (MV) is a core treatment for patients suffering from respiratory disease and failure. However, MV settings are not standardized due to significant inter- and intra-patient variability in response to care, leading to variability in outcome. There is thus a need to personalize MV settings. This research significantly extends a single compartment lung mechanics model with physiologically relevant basis functions, and uses it to identify patient-specific lung mechanics and predict response to changes in MV settings. Nonlinear evolution of pulmonary elastance over positive end expiratory pressure (PEEP) is modelled by a newly proposed, physiologically relevant and simplified compensatory function to enable prediction of pulmonary response for both volume-controlled ventilation (VCV) and pressure-controlled ventilation (PCV), and identified as patient-specific using each patient’s data at a baseline PEEP. Predictions at higher PEEP levels test the validity of the proposed models based on errors in predicted peak inspiratory pressure (PIP) in two VCV trials and volume (PIV) in one PCV trial. A total of 210 prediction cases over 36 patients (22 VCV; 14 PCV) yielded absolute predicted PIP errors within 1.0 cmH₂O (2.3%) and 3.3 cmH₂O (7.3%) for 90% cases in VCV, while predicted PIV errors are within 0.073 L (16.8%) for 85% cases in PCV. In conclusion, a novel deterministic virtual patient model is presented, able to offer accurate prediction of pulmonary response across a wide range of PEEP changes for the two main MV modes used clinically, enabling predictive decision support in real-time to safely personalize and optimize care.

1. Introduction

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) have detrimental impacts on lung stiffness and oxygenation resulting in high morbidity and mortality [1–4]. Mechanical ventilation (MV) is the core treatment for patients suffering from life-threatening respiratory failure in the intensive care unit (ICU). The primary goal of MV is to minimise the work of breathing, ensure adequate gas exchange, and recruit and hold open lung volume to enable recovery [5–9]. However, suboptimal MV settings can lead to over-distension and ventilator induced lung injury (VILI), both of which increase morbidity and mortality [1,6,8–12]. To avoid these harmful effects, protective MV settings have been proposed [1,4,13–15]. Low tidal volume is clinically well-accepted in MV to mitigate VILI, but can lead to alveolar de-recruitment [16–18]. Thus, a protective ‘open lung’ approach uses positive end-expiratory pressure (PEEP) during breathing to prevent alveolar collapse combined with low tidal volume ventilation, thus maintaining an open lung at the end of expiration to ensure sufficient oxygenation and pressure support [6,8,9,18–21]. Staircase recruitment manoeuvres (RMs), comprising a series of incremental and decremental PEEP steps, have been used as one important component in clinical care for recruiting lung volume for lung

* Corresponding author.
E-mail addresses: qianhui.sun@pg.canterbury.ac.nz (Q. Sun), geoff.chase@canterbury.ac.nz (J.G. Chase), cong.zhou@canterbury.ac.nz (C. Zhou), jennifer.knopp@canterbury.ac.nz (J.L. Knopp), Knut.Moeller@hs-furtwangen.de (K. Möller), s.heines@mumc.nl (S.J. Heines), d.bergmans@mumc.nl (D.C. Bergmans), geoff.shaw@cdhb.health.nz (G.M. Shaw).

https://doi.org/10.1016/j.jspc.2021.103367
Received 22 September 2020; Received in revised form 1 November 2021; Accepted 7 November 2021
Available online 13 November 2021
1746-8094/© 2021 Elsevier Ltd. All rights reserved.
protected strategies and assessing the choice of PEEP [6,15,22–24].

RMs with subsequent PEEP changes can be effective in improving oxygenation, while minimizing harm [20,25–27]. However, optimal RM and PEEP settings remain patient-specific, time-varying, and thus not standardized [11,12,18,28–31]. The ‘best’ setting can be different between patients, as well as varying over different conditions and time [5,14,32–35]. An suboptimal PEEP setting can lead to excessive or insufficient support for patients, inducing VILI and leading to higher morbidity and mortality [36,37]. Thus, it is critical to to provide clinicians with better information to monitor patient-specific pulmonary state and forecast the influence of new PEEP settings on pulmonary response for each patient, to improve and personalize care, minimize risk, and maximize care and safety [8,19,34,35]. Therefore, accurate, predictive and patient-specific MV strategies are a major need in advancing care and minimizing MV-associated injury [5,19,34].

Furthermore, two different MV modes are both widely used, volume controlled ventilation (VCV) and pressure controlled ventilation (PCV) [38–40]. VCV allows clinicians to control tidal volume directly, eliminating volutrauma, but they need to be alert to the resulting peak inspiratory pressure (PIP) and barotrauma. Conversely, PCV controls pressure, but risks volutrauma from too large a peak inspiratory volume (PIV) [38]. Both limitations may lead to unexpected VILI [39,41]. To date, no noticeable clinical outcome differences have been seen comparing VCV and PCV [42,43]. Thus, the decision on MV strategies relies on clinician preference, patient characteristics, or patient comfort [38,39]. Therefore, accurate, model-based, and patient-specific pulmonary response prediction is necessary.

In the last two decades, several complex models have been proposed and can effectively capture a large range of nonlinear pulmonary dynamics [34,44–51]. However, their complexity means they suffer poor or non-identifiability [34,52], or are too complex to identify or apply at the bedside [53–59], thus limiting or eliminating their potential for clinical application. Far simpler black box models can be created, but require large amounts of data to train and may lack the ability to capture or describe all physiological features in various situations [58,60,61]. In addition, physiological relevance is important because it supports clinical confidence and use and provides further insight to clinical end-users [52,62], but such black-box models cannot offer physiological relevance. Finally, some models of all types capture lung mechanics well with good personalization of parameters, but are poor in predicting the response to changes in care [63–65], lacking the means to offer guidance to clinicians, and suggesting the identified parameters may not be correct. However, accurate prediction is a major need in guiding and improving the safety and efficacy of clinical MV treatment [66–68]. Thus, there is a need for simpler, identifiable, physiologically relevant models which can offer accurate prediction to changes in care by capturing the evolution of lung mechanics as MV parameters change [34,52].

Currently, while several models can identify data [9,11,44,69–71], the authors are aware of only one approach able to accurately predict outcomes from changes in MV care for resulted airway pressure for VCV and tidal volume for PCV [8,19,72]. These approaches use physiologically relevant basis functions to define respiratory mechanics over all possible pressures and volumes seen in MV, which is uncommon [35,58]. However, while they predict well, the basis functions proposed are independent of known PEEP levels and changes, creating complexity in understanding and implementation, especially for PCV predictions. Thus, if accurate prediction can be obtained with a simpler model where elastance evolution as PEEP changes is captured as a function of PEEP, it could provide an easier, more intuitive, and clinically applicable approach in clinical use.

This research presents physiologically relevant, simpler, basis functions to estimate elastance and resistance evolution as MV parameters change using the same clinically validated single compartment lung mechanics model as previous studies [59,73]. It is validated by assessing prediction error when made patient specific using data from one single

PEEP level to predict pressure and flow at higher PEEP levels. Such a predictive model would offer the ability to quantify the trade-off or compromise between increasing basis function simplicity and improving clinical utility.

2. Methods

2.1. Patient data

Pressure and flow data from 36 mechanically ventilated ICU patients (4 from the CURE pilot trial [74], 18 from the McREM pilot trial [19,75], and 14 from the Maastricht pilot trial) were used to validate the method developed in this study.

2.1.1. VCV trials

In the CURE and McREM trials, all 22 patients were fully sedated and intubated under invasive volume-controlled ventilation, with tidal volume set to 6–8 ml/kg in CURE [76,77] and 8 ± 2 ml/kg in McREM (both based on ideal body weight). The two studies had consistent inclusion criteria of PaO2/FiO2 < 300 mmHg and PaO2/FiO2 < 298 mmHg for CURE and McREM, respectively, which is part of ARDS severity scoring system [2].

2.1.1.1. CURE trial. The CURE trial was conducted on 4 patients at Christchurch Hospital ICU in August 2016 (ANZTR number: ACTRN1261300106730) [74,76]. Demographics are shown in Table 1. Pressure and flow data in this study were sampled at 50 Hz [76].

Spontaneous breathing was prevented using sedation with muscle relaxants during RMs, to minimise asynchrony [44,78–80]. Two staircase RMs were applied to each patient with increments and decrements of 4 cmH2O, consisting of 2 sets, Set 1 and Set 2, with increasing PEEP levels and 2 sets with decreasing PEEP levels, as shown in Fig. 1 (a) [77]. Every set had six increasing or decreasing PEEP levels, while only five PEEP levels were used in Set 1 of Patient 1 by clinical choice. In this study, only sets with increasing PEEP levels are studied. Thus, there are a total of 47 steps across 8 sets for 4 patients, from which 8 cases are used for identifying the model at the lowest PEEP level. The remaining 39 cases are used for prediction and model validation across increasingly large PEEP intervals up to 20 cmH2O.

2.1.1.2. McREM trial. The McREM trial was conducted across eight ICUs from September 2000 to February 2002. Data were sampled at 125 Hz [75]. Demographics are shown in Table 2.

A total of 18 patients from a total of 28 in the McREM trial were selected as they underwent one complete increasing staircase RM where PEEP was set to increase at increments of 2 cmH2O, as shown in Fig. 1 (b). During the protocol, an end-inspiratory hold of 0.2 s was set for all 18 patients [75]. In this study, the identification procedure is applied at PEEP = 10 cmH2O instead of ZEEP (zero end-expiratory pressure) because starting at PEEP = 10 cmH2O creates a clear and equal comparison with the other trial datasets in this study. Overall, this trial yields 100 cases, from which 18 cases are used for identification and the remaining 82 cases are used for prediction and model validation, with increasing PEEP intervals up to 16 cmH2O.

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Length of MV (days)</th>
<th>Clinical Diagnostic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>33</td>
<td>23</td>
<td>Peritonitis</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>77</td>
<td>24</td>
<td>Legionella pneumonia</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>61</td>
<td>23</td>
<td>Staphylococcus Aureus pneumonia</td>
</tr>
<tr>
<td>4</td>
<td>Female</td>
<td>73</td>
<td>2</td>
<td>Streptococcus pneumonia</td>
</tr>
</tbody>
</table>
2.1.2. PCV trial

Data from the Maastricht trial was conducted on 14 patients from November 2017 to February 2018 in Maastricht, Netherlands (METC 17–4–053). Ventilator pressure and flow data was recorded directly from the ventilator. Typical ventilators use hot wire anemometers to measure flow with accuracy to 1 ml/s or less. Volume was integrated for each breath separately from the flow data. All 14 patients are treated with Bi-level Positive Airway Pressure pressure-controlled ventilation. Demographics are shown in Table 3.

Each patient was treated with one full staircase RM with 2 cmH\textsubscript{2}O increments or decrements in PEEP, as shown in Fig. 1 (c). Only the RM arm with incremental PEEP levels is studied for all 14 patients, with model identification starting at 10 cmH\textsubscript{2}O to be consistent with the two VCV trials. Thus, it yields 103 cases, while 14 cases for model identification and the remaining 89 cases are for prediction and validation, with a maximum 16 cmH\textsubscript{2}O PEEP interval.

2.2. Model definition, identification, and prediction

2.2.1. Lung mechanics model

The proposed method is based on a well-validated single compartment lung mechanics model [73]:

\[
P(t) = E^*V(t) + R^*Q(t) + \text{PEEP#}
\]

where \(P(t)\) is airway pressure (cmH\textsubscript{2}O), \(V(t)\) is the tidal volume delivered (L), \(Q(t)\) is the flow (L/s), and PEEP is the positive end-expiratory pressure (cmH\textsubscript{2}O). Pulmonary elastance (cmH\textsubscript{2}O/L) and pulmonary resistance (cmH\textsubscript{2}O*s/L) are defined as \(E\) and \(R\), respectively.

2.2.2. Identification

At baseline PEEP, for all VCV and PCV trials, pressure and flow data are used to identify nonlinear evolution of elastance and resistance for each patient and any single breath. These basis functions for elastance, \(E_i(t)\), and resistance, \(R_i(t)\), are defined:

\[
E_i(t) = e_{1i} + e_{2i}^*P_{i}(t), i = 1\
\]

\[
R_i(t) = r_{1i} + r_{2i}^*Q_{i}(t), i = 1\
\]

where \(P_{i}(t)\) and \(Q_{i}(t)\) are the measured pressure and flow data. The values of \(e_1\), \(e_2\), \(r_1\), and \(r_2\) are patient-specific, constant coefficients to be identified for each patient. They can be identified from any single breath, and are identified at the baseline PEEP level for each
patient in this study.

The elastance basis function, Equation (2), is significantly simplified from the one used in [8,19,35], which defines \( E = f(P(t), V(t)) \). The functions in Equation (2)-(3) remain constant for all further PEEP levels using coefficient values identified at a given PEEP level for each patient. The accuracy of this choice of coefficients across all clinically realistic ranges of pressure and flow is tested in the accuracy of prediction results using the identified model.

\[
P_{\text{PEEP}}(i) = \frac{\text{fitted } P_{\text{IP}} - \text{clinical } P_{\text{IP}}}{\text{clinical } P_{\text{IP}}}
\]

(4)

Thus, in this step, \( e_1 \), \( e_2 \), \( r_1 \), and \( r_2 \) are identified, while the resulting \( E_i \) and \( R_i \) at \( i = 1 \), and \( P_{\text{PEEP}} \) can be calculated with known or identified data and values.

### 2.2.3. Prediction

In this approach, a subscript, \( i \), is used to indicate PEEP level, where \( P_{\text{PEEP}} \) (\( i = 1 \)) is the baseline PEEP level to which the model is identified, and \( P_{\text{PEEP}} \) is the \( i \)th applied PEEP level. In the three studied pilot trials, the maximum is \( i = 6 \) in the CURE trial, \( i = 9 \) in the McREM trial, and \( i = 8 \) in the Maastricht trial, where the McREM and Maastricht trials used smaller \( \Delta \text{PEEP} \) steps.

#### 2.2.3.1. Elastance and resistance prediction

In the modelling approach presented here, a compensatory coefficient, \( \Phi_i \), is proposed aiming to capture the nonlinear evolution of elastance over PEEP for all three trials and calculated as a unit-less value. For \( P_{\text{PEEP}} \) levels (\( i > 1 \)), the function of \( \Phi_i \) is defined with a clinically selected \( P_{\text{PEEP}} = 24 \text{ cmH}_2O \):

\[
\Phi_i = \left\{ \begin{array}{ll}
(1 + P_{\text{PEEP}}^{\min})^2, & i = 2 \\
\Omega_1^* \Delta \text{PEEP}, & i > 2 \\
\Theta_2^* \Delta \text{PEEP} - \Phi_i^* (P_{\text{PEEP}} - P_{\text{PEEP}}^{\min})^2, & i > 2 \\
\end{array} \right.
\]

(5)

while \( \Omega_1 = 0.0174 \) in the CURE trial and \( 0.0087 \) in both the McREM and Maastricht trials, and \( \Theta_2 = |P_{\text{PEEP}}^{\min}} - 0.0123 \) for all trials. \( \Delta \text{PEEP} = \text{PEEP} - \text{PEEP}_1 \), where \( \text{PEEP} \) is the currently applied PEEP level. The values for \( \Omega_1 \) and \( \Theta_2 \) were optimized parametrically by line search. In the CURE trial, \( \Delta \text{PEEP} \) is 4 \text{ cmH}_2O clinically, while in the McREM trial and the Maastricht trial it is 2 \text{ cmH}_2O. Thus, \( \Omega_1 \) is reasonably decreased to half the value used for the CURE trial (\( \Omega_1 = 0.0174 \rightarrow 0.0087 \)), while \( \Theta_2 \) and \( P_{\text{PEEP}}^{\min} \) remain the same. Hence, the parameters are given over all three trials and two MV modes.

Thus, elastance is predicted for \( P_{\text{PEEP}} \) levels (\( i = 2, 3, 4, ... \)) using:

\[
E_i(t) = e_1^* \sum_{i=1}^{i=2} \Phi_i + e_2^* P_{\text{PEEP}}(i)^* \sum_{i=2}^{i=2} \Phi_i + ... + \sum_{i=2}^{i=2} \Phi_i
\]

(6)

Resistance is assumed to be constant over all PEEP levels for each patient as identified at \( P_{\text{PEEP}}^{\min} \) (\( i = 1 \)) [19,35,72], yielding:

\[
R_i(t) = r_1 + r_2^* Q_i(t) \#
\]

(7)

#### 2.2.3.2. Pressure prediction for VCV

For VCV, the CURE trial, and the McREM trial, predicted airway pressure is the independent output variable. Pressure prediction from \( P_{\text{PEEP}} \) to a new \( P_{\text{PEEP}} \) level can be calculated with predicted elastance and resistance:

\[
P_i(t) = E_i(t)^* V_i(t) + R_i(t)^* Q_i(t) + P_{\text{PEEP}} \#
\]

(8)

where \( E_i(t) \) and \( R_i(t) \) are obtained from Equations (6) – (7).

#### 2.2.3.3. Volume and flow prediction for PCV

For PCV, the Maastricht trial, since pressure is the known input, instead of tidal volume and flow, tidal volume is the predicted variable, using:

\[
V_i(t) = \frac{P_i(t) - P_{\text{PEEP}} - R_i(t)^* Q_i(t)}{E_i(t)} \#
\]

(9)

where \( E_i(t) \) and \( R_i(t) \) are obtained from Equations (6) – (7).

### 2.3. Validation and error analysis

In this study, the same error metrics are used to describe the results for both identification and prediction. PIP is the critical clinical indicator in VCV, as it is related to ventilator induced lung injury (VILI) due to pulmonary barotrauma [6,81,82]. Equally, PIV is the key indicator during PCV [39]. Errors are presented as absolute difference (cmH\(_2\)O and L). Root-mean-square (RMS) error is also used to show prediction error in pressure and reproducibility of the \( P(t) \) trajectory over an entire breath in VCV trials, and volume prediction errors and the reproducibility of \( V(t) \) trajectory in PCV trial.

### 2.4. Sensitivity analysis

Equation (5) relies on fixed values for \( \Omega_1 \), \( \Theta_2 \), and \( P_{\text{PEEP}}^{\min} \). While \( P_{\text{PEEP}}^{\min} \) is clinically justified, the \( \Omega_1 \) and \( \Theta_2 \) values are tested across a range of \( \pm 5\% \), \( \pm 10\% \), and \( \pm 15\% \) individually and jointly in a sensitivity analysis to quantify robustness in addition to the three independent data sets and different MV modes used in validation. Mixed changes, such as \( +15\% \) for one variable and \( -15\% \) for the other, are also run, although changes of the same sign are expected to produce the largest errors based on Equation (5). Thus, a total of 48 combinations of \( \Omega_1 \) and \( \Theta_2 \) are analysed in this approach. The same error metrics are reported to assess model robustness to these parameter value choices.

### 3. Results

#### 3.1. VCV trials prediction

##### 3.1.1. Elastance evolution and prediction

Fig. 3 (a) shows an example of elastance evolution for the CURE trial Patient 4, Set 1 across 6 PEEP levels, identified at PEEP = 11 cmH\(_2\)O and predicting response at higher PEEP levels. Fig. 3 (b) shows an example for Patient 15 across 6 PEEP levels in the McREM trial, identified at PEEP = 10 cmH\(_2\)O and then predicting response, where \( T_0 \) is the time when inspiration ends and reaching maximum tidal volume. Typical prediction cases are shown in Fig. 4, with low absolute median pressure predicted error of 0.25 cmH\(_2\)O, 0.46 cmH\(_2\)O and PIP error of 0.23 cmH\(_2\)O, 0.58 cmH\(_2\)O for Patient 1, Set 3 in CURE and Patient 14 in McREM, respectively.

##### 3.1.2. Pressure prediction

Prediction uses the first PEEP level to identify patient-specific model parameters and then predicts the response at higher PEEP levels. Absolute prediction errors (cmH\(_2\)O) of PIP and RMS with median pressure error over the whole breath and interquartile range (IQR) for both two VCV trials are shown in Table 4. Cumulative distribution functions (CDFs) and boxplots for prediction error as a function of \( \Delta \text{PEEP} \) interval showing absolute predicted PIP error (cmH\(_2\)O) are given in Fig. 5 for the CURE trial and Fig. 6 for the McREM trial. For both two VCV trials, the predicted error is slightly larger with larger \( \Delta \text{PEEP} \), which is reasonable and expected. It is worth noting with larger \( \Delta \text{PEEP} \), the clinical PIP is also increasing, and thus the percentage errors of PIP prediction do not have noticeable relationship with \( \Delta \text{PEEP} \). Finally, Fig. 7 (a) shows the correlation of predicted and measured PIP values with \( R^2 = 0.99 \) for CURE and \( R^2 = 0.88 \) for McREM showing a high level of prediction accuracy (\( R^2 = 0.94 \) overall).
3.2. PCV trial prediction

Prediction outcome of volume in PCV basing on base PEEP level, absolute prediction errors of PIV (L) and RMS errors (L), are shown with median prediction error and IQR in Table 5. Correlation for predicted and measured PIV is shown in Fig. 7 (b) with $R^2 = 0.74$. It is clinically acceptable, and 74% of predictions are greater than the clinical value, which can lead to a more conservative treatment choice and thus lower the risk of volutrauma. A typical prediction case for predicted volume in PCV is shown in Fig. 8, with median predicted volume error of 0.018 L over the whole breath trajectory and PIV error of 0.027 L.

3.3. Sensitivity analysis

The values of $\theta_1$ and $\theta_2$ were optimised parametrically by line search. To quantify the impact of this choice of values and decision to used fixed values, $\theta_1$ and $\theta_2$ are modified $\pm 5\%$, $\pm 10\%$, and $\pm 15\%$ individually and jointly. These changes yield further 48 analyses. The maximum changes of predicted PIP error (cmH$_2$O), PIV error (L), and RMS error (cmH$_2$O, L) are recorded and compared with those form the initial values of $\theta_1$ and $\theta_2$, as shown in Table 6 for VCV trials and the PCV trial.
3.4. Model identification quality

Prediction accuracy is dependent on a good identification at the base PEEP level. For VCV trials, identification difference (cmH\textsubscript{2}O) for first PEEP level of 22 identification cases are presented in Table 7. Fig. 9 (a) shows the correlations of model identification, identified PIP and measured PIP, are R\textsuperscript{2} = 0.87 in CURE, R\textsuperscript{2} = 0.96 in McREM, and R\textsuperscript{2} = 0.98 overall. For the PCV trial, identification outcomes for tidal volume (L) is also provided in Table 7, while the correlation of model identification is shown in Fig. 9 (b) with R\textsuperscript{2} = 0.99.

4. Discussion

The personalized, predictive virtual patient model presented uses only data from the first clinically relevant PEEP level to predict the respiratory mechanics and response at higher PEEP, where ΔPEEP can be up to 20 cmH\textsubscript{2}O, a clinically unrealistically change used only to validate the model. Changing PEEP is a key setting to optimise MV care and outcomes [6,12,31]. This overall outcome is achieved using a relatively simple first order single compartment lung mechanics model and physiologically relevant basis functions for elastance and resistance. It is simplified from more complex, and potentially less intuitive, virtual patient models with equally accurate prediction [8,19,35].

Similar to Morton et al [8,19,35,72], resistance is assumed constant across all PEEP levels, as identified at the first PEEP level. Given the relatively low prediction errors, assessing any evolution in resistance would add complexity for minimal gain. Morton et al treated elastance
and its evolution as a more complex function of both volume and pressure. It yielded very good results, but was much higher in complexity, and had some higher prediction errors. Moreover, the proposed approach also yields clinically acceptable results in PCV, which is more difficult to simulate than VCV trials because the two unknown variables of flow and volume are changing simultaneously. Hence, the greater simplicity in the model presented could offer a better approach given to similar to improved prediction performance for both VCV and PCV pilot trials.

The cost of this model simplification is a loss of physiological information, which may concern some clinicians. While effective, it does not have the physiological and clinical relevance of the residual volume ($V_{frc}$) calculation calculated and predicted by Morton et al [8,19,35,72]. $V_{frc}$ volume is the volume captured by ΔPEEP holding more of the lung open at the end of expiration. Thus, this model is effective and generalizes well across MV modes and patients, but may not meet some clinicians requirements or provide greater physiological or clinical insight. This outcome is expected, and occurs in many modelling areas.

In particular, considering the nonlinear evolution of elastance, a compensatory equation is proposed in Equation (5). It successfully estimates elastance other approaches did not capture as well [8,19]. The compensatory equation is a function of the known ΔPEEP, applied PEEP level, identification error of base PEEP, and an assumed general PEEP max. PEEP max is suggested as an internal factor in the nonlinear evolution of elastance, set as 24 cmH2O in this approach, which is clinically typical and justified maximum PEEP level and worked well for all 210 predictions. Fig. 3 presents the clear nonlinear relationship between PEEP and elastance, while the turning points vary with patients and data sets. This performance matches clinically observed evolution in [1,32,69]. However, despite being a personalized approach, it relies on correlation and set values for PEEP max , $\vartheta 1$ and $\vartheta 2$ , which may not generalize in

### Table 5

<table>
<thead>
<tr>
<th>Prediction outcome for PCV trial</th>
<th>Maastricht trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prediction cases</td>
<td>89 cases</td>
</tr>
<tr>
<td>Maximum ΔPEEP</td>
<td>16 cmH2O</td>
</tr>
<tr>
<td>PIV error (L)</td>
<td>median 0.037</td>
</tr>
<tr>
<td></td>
<td>[IQR] [0.020, 0.058]</td>
</tr>
<tr>
<td>RMS error (L)</td>
<td>median 0.043</td>
</tr>
<tr>
<td></td>
<td>[IQR] [0.034, 0.063]</td>
</tr>
</tbody>
</table>

Fig. 6. CDFs plots of predicted absolute PIP error (cmH2O) for all 82 prediction cases (a) and boxplot of absolute PIP error (cmH2O) with ΔPEEP (b) for the McREM trial.

Fig. 7. (a) Predicted PIP vs Clinical PIP ($R^2 = 0.99$ in CURE, $R^2 = 0.88$ in McREM, and $R^2 = 0.94$ overall); (B) Predicted PIV vs Clinical PIV ($R^2 = 0.74$ in Maastricht).
In contrast, the robustness of prediction performance across independent data sets and MV modes shows it generalized well enough over the studied data sets. Overall, these simplifications and choices represent a loss of physiological information, and a potentially too simple model for broad clinical use, where this study needs more clinical data for a more complete validation.

Similar to this approach, Vicario et al. [83] used an added physiological constraint which is estimated for respiratory muscle pressure to help illustrate and estimate the nonlinear behaviour of the lungs. These results offer an effective way to estimate the pulmonary elastance and resistance. However, due to its time-varying physiological constraint equation, the results may have more instability and also lack generality and mechanical or physiological relevance. However, this independent study result still indicates the impact of such assumptions and constraints on lung mechanics and response, which is also seen in this study. In this case, the physiological compensatory equation employed will be the same constant during each PEEP level. Thus, it is more stable than the one used in Vicario et al.

In predicting tidal volume and airway flow for the PCV trial, the performance between volume prediction and flow prediction is not consistent. Considering the very good prediction outcomes in VCV trials, a median PIV prediction error with 0.037 L is acceptable, while biased errors to higher PIV could lead to a clinically preferable conservative decision. This result is achieved with a simple calculation, which means convergence problems are avoided with a low computational cost. Finally, it is important to note these sets of results predict pulmonary response for changing MV inputs (PEEP), where only Morton et al. [8,19,35,72] have provided such results previously. Thus, comparison of prediction errors is favourable in comparing to model-identified errors and to prior work by Morton et al.

A sensitivity analysis of the values of \( \theta_1 \) and \( \theta_2 \) is shown in Table 6. Among the 48 analysed sets, the median predicted absolute median PIP error in CURE trial increases 0.22 cmH\(_2\)O from the initial baseline value choice, while \( \theta_1 \) and \( \theta_2 \) are both 15% smaller, which also yielded a largest median PIP error increasing of 0.07 cmH\(_2\)O in the Maastricht trial. In the Maastricht trial, the median PIV prediction error increases with a 0.004 L difference under same set and 0.002 L for RMS error. Thus, this approach is robust to these parameter choices.

This study is tested with three independent data sets including two VCV trials and one PCV trial covering a total of 36 patients under various diagnostic and situations. Generalization is reasonably demonstrated, and more data with different PEEP settings, tidal volume decisions, and MV strategies need to be analysed to ensure more widespread generality to more completely quantify the impact of the simplifying choices made. These studies require more data than available for this proof-of-concept validation, although the initial results presented here show significant promise.

Overall, the proposed model provides accurate and robust predictions even with a clinically unrealistic PEEP up to 20 cmH\(_2\)O and 16 cmH\(_2\)O for VCV and PCV trials, respectively, avoiding complicated procedures or iterative calculation seen in limited prior works [19,35,72]. It is computationally efficient to identify the required parameters for following prediction without any training or updating in black box models, thus minimizing computation, identifiability, and generalisation issues seen in these other approaches and more complex models. Finally, despite simplification, nonlinear elastance evolution is effectively captured and yields accurate predictions across 3 clinical trials (2 VCV, 1 PCV), while offering new insight into the required level of complexity for a virtual patient model for clinical use in MV. Clinically, defining the elastance evolution as a function of the key changing MV parameter, PEEP, ensures the model is more intuitive and easy to understand as evolution is solely a function of the input parameter being changed. All these outcomes significantly extend prior works and offer new insight into modelling of pulmonary mechanics and the potential use of such models to guide clinical care.
choices. The overall model showed results accurate enough for it to be testing. All fixed parameter choices were checked for robustness using a control and validating these virtual patient models before clinical testing. All fixed parameter choices were checked for robustness using a sensitivity test to ensure there was no hidden dependence on these choices. The overall model showed results accurate enough for it to be clinically tested in prospective clinical studies to demonstrate its potential safety, efficacy, and ability to improve care and outcomes.

CRediT authorship contribution statement


Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work was supported by the NZ Tertiary Education Commission (TEC) fund MedTech CoRE (Centre of Research Excellence; #3705718) and the NZ National Science Challenge 7, Science for Technology and Innovation (2019-S3-CRS). The authors also acknowledge support from the EU H2020 R&I programme (MSCA-RISE-2019 call) under grant agreement #872488 — DCPM.

References
